Paula J. Bucko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paula J. Bucko has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- John D. Scott
Department of Pharmacology, University of Washington School of Medicine, Seattle, Washington
3 shared publications Akansha Bhat
University of Washington, United States
2 shared publicationsIrvin Garcia
University of Washington, United States
2 shared publicationsChloe K Lombard
Department of Chemistry, University of Washington, Seattle, United States
1 shared publication- Dustin J. Maly
Department of Chemistry, University of Washington, Seattle, WA, USA
1 shared publication - F. Donelson Smith
Sensei Biotherapeutics, Inc., Rockville, Maryland
1 shared publication
Latest Publications
- Open Access
- 1 October 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (40) , 13784-13797
Gravin-associated kinase signaling networks coordinate γ-tubulin organization at mitotic spindle poles
- 1 October 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (40) , 13784-13797
Open AccessGravin-associated kinase signaling networks coordinate γ-tubulin organization at mitotic spindle poles
- Open Access
- 24 December 2019
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 8
Subcellular drug targeting illuminates local kinase action
Deciphering how signaling enzymes operate within discrete microenvironments is fundamental to understanding biological processes. A-kinase anchoring proteins (AKAPs) restrict the range of action of protein kinases within intracellular compartments. We exploited the AKAP targeting concept to create genetically encoded platforms that restrain kinase inhibitor drugs at distinct subcellular locations. Local Kinase Inhibition (LoKI) allows us to ascribe organelle-specific functions to broad specificity kinases. Using chemical genetics, super resolution microscopy, and live-cell imaging we discover that centrosomal delivery of Polo-like kinase 1 (Plk1) and Aurora A (AurA) inhibitors attenuates kinase activity, produces spindle defects, and prolongs mitosis. Targeted inhibition of Plk1 in zebrafish embryos illustrates how centrosomal Plk1 underlies mitotic spindle assembly. Inhibition of kinetochore-associated pools of AurA blocks phosphorylation of microtubule-kinetochore components. This versatile precision pharmacology tool enhances investigation of local kinase biology.
- 24 December 2019
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 8
Open AccessSubcellular drug targeting illuminates local kinase action
Deciphering how signaling enzymes operate within discrete microenvironments is fundamental to understanding biological processes. A-kinase anchoring proteins (AKAPs) restrict the range of action of protein kinases within intracellular compartments. We exploited the AKAP targeting concept to create genetically encoded platforms that restrain kinase inhibitor drugs at distinct subcellular locations. Local Kinase Inhibition (LoKI) allows us to ascribe organelle-specific functions to broad specificity kinases. Using chemical genetics, super resolution microscopy, and live-cell imaging we discover that centrosomal delivery of Polo-like kinase 1 (Plk1) and Aurora A (AurA) inhibitors attenuates kinase activity, produces spindle defects, and prolongs mitosis. Targeted inhibition of Plk1 in zebrafish embryos illustrates how centrosomal Plk1 underlies mitotic spindle assembly. Inhibition of kinetochore-associated pools of AurA blocks phosphorylation of microtubule-kinetochore components. This versatile precision pharmacology tool enhances investigation of local kinase biology.
- Open Access
- 11 July 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (30) , 201607745-37
AKAP220 manages apical actin networks that coordinate aquaporin-2 location and renal water reabsorption
Filtration through the kidney eliminates toxins, manages electrolyte balance, and controls water homeostasis. Reabsorption of water from the luminal fluid of the nephron occurs through aquaporin-2 (AQP2) water pores in principal cells that line the kidney-collecting duct. This vital process is impeded by formation of an “actin barrier” that obstructs the passive transit of AQP2 to the plasma membrane. Bidirectional control of AQP2 trafficking is managed by hormones and signaling enzymes. We have discovered that vasopressin-independent facets of this homeostatic mechanism are under the control of A-Kinase Anchoring Protein 220 (AKAP220; product of the Akap11 gene). CRISPR/Cas9 gene editing and imaging approaches show that loss of AKAP220 disrupts apical actin networks in organoid cultures. Similar defects are evident in tissue sections from AKAP220-KO mice. Biochemical analysis of AKAP220-null kidney extracts detected reduced levels of active RhoA GTPase, a well-known modulator of the actin cytoskeleton. Fluorescent imaging of kidney sections from these genetically modified mice revealed that RhoA and AQP2 accumulate at the apical surface of the collecting duct. Consequently, these animals are unable to appropriately dilute urine in response to overhydration. We propose that membrane-proximal signaling complexes constrained by AKAP220 impact the actin barrier dynamics and AQP2 trafficking to ensure water homeostasis.
- 11 July 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (30) , 201607745-37
Open AccessAKAP220 manages apical actin networks that coordinate aquaporin-2 location and renal water reabsorption
Filtration through the kidney eliminates toxins, manages electrolyte balance, and controls water homeostasis. Reabsorption of water from the luminal fluid of the nephron occurs through aquaporin-2 (AQP2) water pores in principal cells that line the kidney-collecting duct. This vital process is impeded by formation of an “actin barrier” that obstructs the passive transit of AQP2 to the plasma membrane. Bidirectional control of AQP2 trafficking is managed by hormones and signaling enzymes. We have discovered that vasopressin-independent facets of this homeostatic mechanism are under the control of A-Kinase Anchoring Protein 220 (AKAP220; product of the Akap11 gene). CRISPR/Cas9 gene editing and imaging approaches show that loss of AKAP220 disrupts apical actin networks in organoid cultures. Similar defects are evident in tissue sections from AKAP220-KO mice. Biochemical analysis of AKAP220-null kidney extracts detected reduced levels of active RhoA GTPase, a well-known modulator of the actin cytoskeleton. Fluorescent imaging of kidney sections from these genetically modified mice revealed that RhoA and AQP2 accumulate at the apical surface of the collecting duct. Consequently, these animals are unable to appropriately dilute urine in response to overhydration. We propose that membrane-proximal signaling complexes constrained by AKAP220 impact the actin barrier dynamics and AQP2 trafficking to ensure water homeostasis.